We are a privately held pharmaceutical company focused on the development and commercialization of JATENZO®, our oral testosterone (T) replacement product. JATENZO is a new FDA approved T-replacement therapy. It is the first FDA approved oral formulation of a T prodrug, namely, testosterone undecanoate (TU).
Based on our clinical trial results, JATENZO restores circulating T to normal levels and overcomes the safety challenges, such as liver toxicity, historically associated with oral androgen-replacement therapies.
Our investors are Thomas, McNerney & Partners, L.P., H.I.G. BioHealth Partners, ProQuest Investments, C-Bridge Capital Partners, LLC, BVCF Management, Ltd. and Pavilion Capital Pte Ltd.